Table 1 Summary characteristics of included studies
| Â | One-stage revision | Two-stage revision |
|---|---|---|
Eligible studies | ||
 Total number of studies included | 2 | 7 |
Participants | ||
 Total number of participants | 7 | 87 |
 Total number of re-infections | 1 | 11 |
 Median (IQR) age (years) | 64.9 (62.7–67.0) | 64.7 (59.7–65.0) |
 Median (IQR) males (%) | 0.0 (0.0–0.0) | 31.0 (29.5–35.8) |
Location | ||
 Europe | 2 (7) | 4 (59) |
 North America | – | 3 (28) |
 Asia | – | – |
Study and surgery characteristics | ||
 Median (IQR) time from index surgery to infection diagnosis (months) | 40.5 (40.5–40.5) | 38.0 (24.0–51.9) |
 Median (IQR) duration of infection symptoms (days) | – | 60.4 (60.4–60.4) |
 Median (IQR) time from index surgery to revision surgery (months) | – | 57.1 (48.2–66.0) |
 Median (IQR) from infection diagnosis to revision surgery (months) | – | 15.0 (15.0–15.0) |
 Median (IQR) interval between stages (months) | NA | 6.1 (4.7–7.7) |
 Median (IQR) follow-up (years) | 5.4 (4.0–6.8) | 4.1 (3.0–4.3) |
 Median (IQR) duration of antibiotics (days) | – | 30.5 (11.3–49.7) |
 Median (IQR) duration of IV antibiotics (days) | 37.2 (37.2–37.2) | 8.8 (8.8–8.8) |
 Median (IQR) duration of oral antibiotics (days) | – | 2.5 (2.5–2.5) |
 Methodological quality (IQR) | 10.5 (10.0–11.0) | 10.0 (10.0–11.0) |
Baseline clinical characteristics | ||
 Median (IQR) Range of motion (°) | – | 72.0 (50.0–94.0) |
 Median (IQR) Extension | – | 36.3 (36.3–36.3) |
 Median (IQR) Flexion | – | 101.3 (101.3–101.3) |
 Median (IQR) MEPS | – | 28.0 (22.9–52.5) |
 Median (IQR) Pain score | – | 15.0 (15.0–15.0) |